Type 2 Diabetes Clinical Trial
| Verified date | April 2016 |
| Source | University of Alberta |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Institutional Review Board |
| Study type | Interventional |
In Canada, there is a fast-growing population with diabetes, and the majority of diabetes
cases are type 2 diabetes (T2D). Diabetes and its complications, such as cardiovascular
diseases, eye disease and foot disease, impair the quality of life and life expectancy.
Chinese are the second largest visible minority in Canada. The diabetes incidence increased
much more rapidly in the Canadian population of Chinese origin compared with that of
European origin in past decades. Cultural factors are very likely to affect individual
behaviour in diabetes treatment. Both international and Canadian diabetes organizations have
recognized the importance of taking into account the cultural background and individual
preferences in diabetes treatment.
However, there lacks cultural relevant nutritional recommendations or guidelines for Chinese
Canadians except some literally translated materials which may not be culturally relevant.
In order to fill the gap, the investigators have developed a Chinese menu plan that includes
commonly consumed Chinese dishes with nutrients breakdown and cooking tips to provide
guidance for patients in their daily meal planning. This menu plan is a cultural translation
of the Canadian nutritional guidelines, which is urgently needed among Chinese immigrants
with T2D in Edmonton, according to our previous needs assessment.
In this pilot test, the investigators will examine the feasibility and effectiveness of the
Chinese menu plan. Twenty Chinese with T2D in Edmonton will be recruited to use the menu
plan for 3 consecutive months and relevant indices of T2D will be tested as indicators of
effectiveness. Feedback from participants will be obtained through one-on-one interviews and
appropriate modifications will be made to the menu plan.
| Status | Completed |
| Enrollment | 17 |
| Est. completion date | December 2015 |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 35 Years and older |
| Eligibility |
Inclusion Criteria: - = 35 years of age; - diagnosed with T2D or prediabetes; - baseline hemoglobin A1C = 6.0%; - treatment with lifestyle, and/or oral hypoglycemic medications or insulin; - Chinese origin; - able to read and write Chinese or English Exclusion Criteria: - severe gastrointestinal or renal problems that would preclude a diet according to the Nutrition Therapy Guidelines for Diabetes |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| University of Alberta |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Dietary intake (3-day food record) | Intake assessed pre-post intervention using a 3-day food record | 12 weeks | No |
| Secondary | Hemoglobin A1c (A1c) | Hemoglobin A1c measured in capillary blood pre-post intervention | 12 weeks | No |
| Secondary | Body mass index (BMI) | Body mass index calculated from weight measured pre-post and height measured pre-intervention | 12 weeks | No |
| Secondary | Waist circumference | Waist circumference measured pre-post intervention | 12 weeks | No |
| Secondary | Lipid profile | Measurement of fasting serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low density lipoprotein cholesterol (LDL) | 12 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |